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2Abstract
Microperimetry is a novel technique for assessing visual function and appears particularly 
suitable for age-related macular degeneration (AMD). Compared to standard automated 
perimetry (SAP), microperimetry offers several unique features. It simultaneously images the 
fundus, incorporates an eye tracking system to correct the stimulus location for fixation loss, 
and identifies any preferred retinal loci. A systematic review of microperimetry in the 
assessment of visual function in AMD identified 680 articles. Of these, 52 met the inclusion 
criteria. We discuss microperimetry and AMD in relation to disease severity, structural imaging 
outcomes, other measures of visual function, and evaluation of the efficacy of surgical and/ or 
medical therapies in clinical trials.  The evidence for the use of microperimetry in the functional 
assessment of AMD is encouraging. Disruptions of the ellipsoid zone  band and retinal pigment 
epithelium (RPE) are clearly associated with reduced differential light sensitivity (DLS) despite 
the maintenance of good visual acuity .  Reduced DLS is also associated with outer segment 
thinning and RPE thickening in early AMD and with both a thickening and a thinning of the 
whole retina in choroidal neovascularization.  Microperimetry, however,lacks the robust diffuse 
and focal loss age-corrected probability analyses associated with SAP, and the technique is 
currently limited by this omission.
Key words: microperimetry, age-related macular degeneration, optical coherence 
tomography, visual function, systematic review
3I. Introduction
Age-related macular degeneration (AMD) 1 is the leading cause of blindness in the developed 
world 66 and accounts for the majority of registerable visual impairment in both the USA and 
the UK 10,37,54. Visual acuity (VA) is the most widely used outcome measure in ophthalmic 
research; however, VA is insufficiently sensitive to detect the early stages of functional loss in 
AMD 42,50. Various other tests of visual function, such as dark adaptation 46, flicker threshold 
15 and photostress recovery time 44 are more sensitive than VA in detecting early functional 
loss in AMD; however, such tests have limited clinical utility because they are time-consuming 
44. There is, therefore, a need for a robust and clinically appropriate technique to assess visual 
function across the macula that is more indicative than VA. 
Microperimetry is similar to standard automated perimetry (SAP) in that it measures the 
differential light sensitivity (DLS), i.e. the minimum luminance of a white spot stimulus 
superimposed upon a white background of uniform luminance necessary to perceive the 
stimulus. Microperimetry, however, is novel in that it uses an eye tracking system to correct 
the position of the stimulus for any changes in fixation. Such a correction is particularly 
appropriate in the later stages of macular disease where unsteady fixation and/ or a preferred 
retinal locus are common. Microperimetry offers the additional benefit of providing a real-time 
en-face image of the posterior pole. The latter is of value in macular disease as it enables 
1 Abbreviations - DLS: Differential light sensitivity, MAIA: Macular Intensity Assessment, SLO: 
Scanning laser ophthalmoscopy, MS: Mean Sensitivity, TD: Total Deviation, MD: Mean 
Deviation, nGA: Nascent geographic atrophy, ORT: Outer retinal tubulations, LLD: Low 
luminance deficit; AREDS: Age-related Eye Disease Study, GA: geographic atrophy,  EZ: 
ellipsoid zone, ELM: external limiting membrane, INL inner nuclear layer; OPL: outer plexiform 
layer, nGA: nascent geographic atrophy, FAF: fundus autofluorescence, NIR-FAF: near-
infrared fundus autofluorescence, anti-VEGF: anti-vascular endothelial growth factor, dB: 
decibel, mfERG: multifocal electroretinography.
4direct comparison between the visual function outcome and the underlying fundus appearance 
2.
The concept of microperimetry was initially introduced clinically in 1981 67. Currently, there are 
two commercially available microperimeters: the Nidek MP-3 (Nidek Technologies, Padova, 
Italy) and the Macular Integrity Assessment microperimeter (MAIA, CentreVue, Padova, Italy).  
These instruments have an improved dynamic range of 34dB (maximum stimulus intensity of 
3183 cdm-²) for the MP-3 and 36dB (318 cdm-²) for the MAIA, compared to 20dB for the two  
earlier commercially available instruments, the MP-1 (128cdm-²) and the Optos optical 
coherence tomography (OCT) scanning laser ophthalmoscope (SLO) (Optos, Dunfermline, 
Scotland, UK) (125cdm-²). The background luminance for the MAIA is 1.27cdm-²; while the 
MP-3 offers the option of either 1.27cdm-² or 10cdm-². The technical specifications of the 
current and earlier microperimeters are reviewed in detail elsewhere 40. The eye-tracking 
systems automatically register the eye position 25 times per second relative either to given 
anatomic landmarks (MP-3) or to each pixel of the fundal image (MAIA).
Mean Sensitivity (MS) is the most common outcome measure in microperimetry and is defined 
as the mean of the DLS obtained across all the designated stimulus locations; however, the 
MS is a summary measure and does not account for the decline in DLS with age. Less 
common, but more appropriate, outcome measures for microperimetry are the Total Deviation 
(TD), defined as the difference between the DLS at a given stimulus location and the 
corresponding age-corrected normal value, and the Mean Deviation (MD), defined as the 
arithmetic mean of the TD obtained across all the designated stimulus locations. A worsening 
of visual function is indicated by an increasingly less positive MS and by an increasingly 
negative TD and MD. 
5Given that the microperimetry is novel and that the design features appear particularly suitable 
for assessing visual function in AMD, we undertook a systematic review to evaluate the 
literature relating to the use of microperimetry for assessing visual function in AMD. 
II. Results
The search identified 674 primary articles. Six additional articles were obtained from the 
references within the primary retrieved articles.  The final number of included articles was 52 
(Figure 1).  
We divided our review into four principle areas that reflected the content of the included 
articles: evaluation of the efficacy of microperimetry in distinguishing between the various 
stages of AMD severity (4 articles), the relationship between microperimetry outcomes and 
structural imaging outcomes (including Spectral Domain Optical Coherence Tomography, SD-
OCT) (21 articles), the relationship between microperimetry outcomes and those of other 
measures of visual function (12 articles), and microperimetry outcomes in the evaluation of 
the efficacy of medical therapy and/ or surgical intervention in the treatment of AMD (17 
articles). 
A. Quality of evidence
The quality of each of the 52 included articles is described in Table 1, which is ordered by 
quality of evidence. The studies were classified as either experimental or observational. Within 
these two classifications, experimental studies were classified as either randomised control 
trial (RCT) or as non-randomised design, which will be referred to as quasi-experimental. 
Observational studies were classified as cross-sectional, case-controlled or case series. None 
of the included studies were cohort studies. Assessment of the quality of reporting showed 
6that over half the articles included in this review had limitations relating to the quality of the 
microperimetry outcome (18 articles) and/ or to the reporting of the SD-OCT methods and 
analysis (11 articles). The reporting of microperimetry stimulus parameters was also generally 
poor, particularly in regard to the description of the stimulus program (i.e., the number, the 
location, and the separation, of the stimuli). 
The method of classification of AMD severity varied between the various studies and limited 
the meaningful comparisons between studies. These comprised the AREDS grading system 
7 (7 articles), the Beckman classification 19 (9 articles), the Wisconsin Age-related Maculopathy 
Grading system 36 (1 article),  and the International Classification and Grading system 8 (2 
articles). Consequently, the classification method utilised in each study is noted, where 
appropriate, throughout this review. 
Similarly, the difference in the stimulus parameters and also in the dynamic range between 
the various microperimeters used, hinder direct comparisons of DLS between studies 1. 
Microperimetry was undertaken by the Nidek MP1 or MP1-S in 29 of the 52 included articles 
3,5,9,12,16,17,23,25,32–35,39,41,43,45,48,49,51,52,55–57,59–63,68 by the Nidek MP3 in 1 27, by the MAIA in 13 
4,6,11,65,69–77, by the Optos Spectral OCT/SLO in 7 13,20,28–30,38,53 and by the Rodenstock SLO 
microperimeter in two articles 18,22. The limited dynamic range of the previously available Optos 
OCT SLO and Nidek MP-1 microperimeters arising from the lower maximum stimulus 
luminance results in ceiling and floor effects compared to the MAIA and MP-3 microperimeters 
40. In particular, the presence of a floor effect can result in underestimation of the depth of the 
field loss. Consequently, the type of microperimeter is specified whenever the perimetric 
outcome is given in decibels (dB).
7B. Microperimetry and AMD severity
Four of the 52 included articles evaluated the efficacy of microperimetry in distinguishing 
between the various stages of AMD severity 16,22,65,70.  Microperimetry with the MAIA is able to 
discriminate between normality and early and intermediate stages of AMD (Age-related Eye 
Disease Study, AREDS 7, grades 2 and 3 respectively) when considered both in terms of the 
group mean MS and of the DLS derived at individual locations 65. In the largest study of this 
kind to date, the group of 200 normal individuals exhibited the highest MS (mean 29.8 dB; SD 
1.7) while within the group of 200 individuals with AMD, the MS for those with early AMD was 
larger (mean 24.9 dB; SD 3.9) than for those with intermediate AMD (mean 21.8 dB; SD 5.4-
-all p<0.001) 65. A comparable, but earlier, study of 30 individuals found a statistically 
significant worsening of both the group mean MS and the group mean MD for intermediate 
AMD (AREDS grade 3) compared to normal individuals 16. For both these studies, the 
magnitudes of the group mean MS reflected the severity of the structural classification of AMD; 
however, the magnitudes of the standard deviations associated with the group mean MS 
indicated overlap between groups. In addition, no criteria for microperimetry were given for 
the optimal differentiation, on an individual basis, between the AMD severities. The analysis 
of the DLS at each individual stimulus location enabled a localised assessment of function that 
was more descriptive of the AMD severity than that provided by the MS 70. 
The reduction in DLS varies with the location and severity of the AMD. Eyes with subfoveal 
neovascular AMD (nAMD) that exhibit severe (absolute) localised parafoveal abnormality (0 
dB, as measured by an early commercially available Rodenstock SLO microperimeter; 
Rodenstock GmbH, Munich, Germany) manifest a normal foveal DLS, enabling central fixation 
to be maintained 22. The likelihood of a dense parafoveal abnormality increases as the duration 
of self-reported symptoms increases 22.
8In summary, the MS derived by microperimetry is reduced in eyes with AMD and is able to 
differentiate, on a group mean basis at least, between levels of disease severity 16,65. The 
evidence, however, is questionable as to whether microperimetry can correctly classify AMD 
disease severity. Characterising the reduction in DLS by location, area and depth enables the 
study of associations with other factors such as disease duration and maintenance of central 
fixation 22. 
C. Microperimetry and structural imaging modalities
Twenty of the 52 included articles were concerned with the relationship between visual 
function and retinal morphology in AMD 3,20,21,27–29,33,34,38,45,51,52,57,59,61,63,73–76, most of which 
used SD-OCT. This section discusses microperimetry outcomes in relation to specific retinal 
layer changes, retinal pseudodrusen, geographic atrophy (GA), and outer retinal tubulations 
(ORTs). 
A typical SD-OCT horizontal line scan of an individual with AMD illustrating the retinal layers 
evaluated in the various studies is shown in Figure 2. The external limiting membrane (ELM) 
appears as a hyper-reflective line, by SD-OCT, in the outer retina just above the ellipsoid zone 
(EZ). The EZ is also visible as a hyper-reflective band, but is not synonymous with a single 
retinal anatomical feature 64. The photoreceptor outer segment layer appears below the EZ 
band and is visible as a hyporeflective line. The retinal pigment epithelium (RPE) layer also 
appears as a hyper-reflective line that is continuous with Bruch’s membrane until disease 
processes cause their separation.
9Reticular pseudodrusen represent a build-up of material  below the RPE and, when viewed by 
SD-OCT, manifest as hyper-reflective triangular shaped deposits located between the RPE 
and the EZ band (Figure 3) 58,80. Geographic atrophy (GA) is the late stage of AMD, with loss 
of retinal structures including the RPE and photoreceptors and the ensuing visibility of the 
underlying choroidal vessels (Figure 4) 27. Nascent geographic atrophy (nGA) as defined by 
Wu and colleagues73 occurs prior to drusen-associated atrophy and has similar risk factors to 
GA and can be visualised by SD-OCT, but not by color fundus photography 73. nGA appears 
by SD-OCT as a breakdown of the outer plexiform layer (OPL) and inner nuclear layer (INL) 
accompanied with a wedge-shaped hyporeflective area in the OPL 78. Finally, ORTs can only 
be visualised by SD-OCT and appear as a hyper-reflective ring with a hyporeflective center 
located within the outer nuclear layer (Figure 5). 
1. Retinal layers
The relationship between outer retinal layer thickness and DLS in early AMD has been 
investigated by comparing RPE and OS thicknesses at locations with and without an abnormal 
DLS (defined as a TD value with a probability of lying within the normal range of p≤ 0.05) 3. 
The OS layer was thinner at locations with an abnormal TD (p<0.01). The OS layer thickness 
was also significantly correlated with both MS and MD obtained using the MP-1 
microperimeter (r=0.62 and r=0.63, respectively, both p<0.01) 3. MS worsens with increased 
thickening of the RPE 3,74,76. A 10μm increase in RPE layer thickness is associated with a 0.29 
dB worsening of MS (p<0.001) obtained  with the MAIA microperimeter 76. 
In eyes with early to intermediate AMD, the MS at locations overlying drusen is statistically 
significantly worse than that at adjacent locations 28,34. EZ band disruption is the strongest 
predictor of DLS at locations with drusen, 28 and the reduction in MS in the presence of EZ 
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band disruption is worse than that in the presence of drusen alone 34. Notably, in the former 
study the stage of AMD was not classified. Individuals exhibiting drusen (excluding nAMD) 
were included and, therefore, any stage of AMD may have been involved 28. In early to late 
atrophic AMD, MS worsens as the EZ band disturbance increases 38,53,74. In nAMD, a 
worsening of EZ band disruption and an increase in central retinal thickness are both 
associated with a reduction in MS (r=-0.79; p<0.001 and r=-0.51; p<0.01, respectively) 38,61. 
Similarly, in nAMD treated with bevacizumab, MS significantly worsened (p<0.01) with 
increase in EZ band disruption 29.  The presence of nAMD, intra-retinal cysts and a focal/ 
localised absence either of the RPE or of the photoreceptor layer are each associated with an 
absolute loss of MS (<0dB) obtained with the MP-1 microperimeter 61. Sub-retinal fluid, intra-
retinal fluid, pigment epithelial detachment (PED) and pseudodrusen are each separately 
associated with relative visual field loss (defined as 1 dB to 8 dB) when measured with the 
MP-1 microperimeter 61.
2. Reticular pseudodrusen
The presence of reticular pseudodrusen in early to intermediate AMD (AREDS grade 2, 3 or 
4 7) is associated with a reduction in MS out to 10° eccentricity 45. Such an association is 
absent in a cohort with intermediate stage AMD (Beckman classification 19) 75. MS out to 4˚ 
eccentricity was associated with reticular pseudodrusen on a univariate basis; however, in a 
multivariate analysis incorporating age, drusen volume, and pigmentary disturbance, the 
association was no longer present 75. One explanation for these findings may simply be the 
difference in classification systems used for the two studies. In early to intermediate AMD 
(Beckman classification19), both scotopic and mesopic group mean MSs, obtained with a 
modified MP-1S microperimeter, were reduced in areas of reticular pseudodrusen (mean 
12.8dB; SD 3.3 and mean 17.2dB; SD 2.5, respectively) compared to areas without (mean 
18.2dB; SD 2.2 and mean 18.4dB; SD 2.5, respectively). The scotopic MS was reduced to a 
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greater extent than the mesopic MS 59. These findings suggest that, in the presence of reticular 
pseudodrusen, rod photoreceptor function is the most affected. It is not clear, however, 
whether the greater reduction in the scotopic MS was caused by differences in the 
measurement range resulting from the two different background luminances enabling scotopic 
and mesopic viewing conditions. Scotopic dysfunction also correlates with outer retinal 
thickness in eyes with reticular pseudodrusen: a 1μm decrease in thickness corresponded to 
a 0.96dB reduction in scotopic MS 59. In another study, the MS was also reduced in the 
presence of pseudodrusen in atrophy-free areas of eyes with GA 63. 
3. Geographic atrophy
In GA, MS has been compared between areas with and without either RPE loss and/ or 
photoreceptor damage 63. The group mean MS, obtained with the MP-1 microperimeter, was 
markedly lower in areas of RPE loss (mean 1.84 dB; SD 2.68; p<0.001) and also in areas with 
photoreceptor damage (mean 6.57 dB; SD 4.13; p<0.001) when compared to areas without 
63. In GA, a thinning or an absence of the RPE, an absence of the external limiting membrane, 
and a thickening of the EZ boundary are each associated with absolute field loss (0dB) 
obtained with the MP-1 microperimeter 57. The group mean MS obtained with the MP-3 
microperimeter at the GA boundary is lower (mean 13.7dB; SD 4.7)  than the group mean MS 
in the area surrounding the GA (mean 20.8dB; SD 3.8); however, the latter is lower than that 
in eyes without GA (mean 23.9dB; SD 2.6) (p<0.001) 27. Another study utilized en-face OCT 
to identify GA boundaries at the choroidal and the outer retinal levels. When the MS was better 
than 10dB, the mean area of GA was larger at the outer retinal level than at the choroidal level; 
however, the areas were similar when the MS was worse than 10dB 51.
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In areas of nGA, the group mean MS measured by MAIA microperimetry is reduced (mean 
20.4 dB; SD 0.8) compared to areas without atrophy (mean 23.8 dB; SD 0.7, p<0.01) and is 
greater than that obtained in areas with drusen associated atrophy (mean 16.4 dB; SD 0.9; 
p<0.01) 73. The area of drusen associated atrophy did not exhibit absolute loss as was the 
case in GA 73. 
Progression of GA can be monitored by fundus autofluorescence (FAF) as the areas of GA 
appear hypo-fluorescent. One study compared the outcome of MP-1 microperimetry to that 
from both near-infrared fundus autofluorescence (NIR-FAF) and short-wavelength FAF 52. The 
associations between severe relative loss (a DLS of not more than 5 dB) and normal and 
hyper-fluorescence outcomes were determined for each FAF technique. It was concluded that 
the outcome from MP-1 microperimetry, in combination with both FAF techniques, allowed 
effective detection and monitoring of GA 52. Another study used microperimetry to evaluate 
SD-OCT FAF and NIR-FAF 20.  As would be expected, DLS was substantially reduced in areas 
of GA, and the imaging techniques were able to detect the presence of GA with differing 
capabilities. SD-OCT was considered to be the most appropriate imaging technique to 
examine GA 20. 
4. Outer retinal tubulations
Outer retinal tubulations (ORTs) are not specific to AMD and are seen more commonly in 
inherited retinal disorders such as  choroideremia and retinitis pigmentosa 24. In AMD, they 
are not a typical feature and can occur in eyes with previous nAMD. The identification of ORTs 
is clinically important as they may be  misinterpreted as either intraretinal or subretinal fluid, 
with the resultant unnecessary treatment 33,79.  In a study of individuals without ORTs who 
were treated for nAMD, the improvement in MS obtained with the MP-1 microperimeter after 
13
12 months was less pronounced in those that developed ORTs (mean 6.31dB, SD 2.5) 
compared to those that did not (mean 9.89dB, SD 5.43; p<0.01). This study, however, did not 
fully describe the stimulus parameters for the microperimetry.
In summary, focal areas of reduced DLS in AMD can be identified by microperimetry and are 
associated with a disruption of the EZ band and/or changes to the RPE 34,38,53,74.  The 
association between reticular pseudrodrusen and MS is equivocal. In early to intermediate 
AMD (AREDS 2, 3 and 4 7), the presence of pseudodrusen is associated with a reduction in 
MS at the macula; 45 however, there was no such association in a different cohort with 
intermediate AMD (Beckman classification19) 75. The differences between areas with and 
without pseudodrusen, for early and intermediate AMD (Beckman classification 19), combined, 
are seemingly most profound under scotopic conditions 59. The reduction in MS is, in general, 
consistent with the presence of retinal lesions apparent by OCT. In the presence of a normal 
retinal appearance by fundus photography, microperimetry detects functional loss arising from 
nGA 27,63,73. 
D. Microperimetry and other measures of visual function.
Fifteen included studies used microperimetry alongside other measures of visual function in 
individuals with AMD  3,5,11,18,23,30,43,45,48,49,56,69,71,72,77.In early AMD (International Classification 
and Grading System8) with distance VAs ranging from 20/20 to 20/40, the corresponding MS 
varied between 19.5dB (SD 0.4dB) and 14.9dB (SD 2.4dB) 3. Similarly, in early to intermediate 
AMD (Beckman classification19) with a distance VA better than 20/40, MS exhibited a greater 
reduction compared to VA and to low luminance VA (LLVA) by 3.0 and 1.9 fold, respectively 
71. A prospective longitudinal study of intermediate AMD (Beckman classification19) 72, 
compared two groups: those graded as progressed, defined as the development of additional 
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structural abnormality visible by colour fundus photography, and those graded as stable with 
unchanged features. No deterioration from baseline in either VA or LLVA was present in either 
group at 12 months; however, small but statistically significant reductions in group mean MS 
(obtained with the MAIA microperimeter) were present in both groups (mean 0.42dB; SE 0.12 
and mean 0.31dB; SE 0.10, respectively) 72. It should be noted, however, that microperimetry 
is only able to measure DLS to a resolution of 1dB, and therefore the clinical significance of 
these findings is limited. An additional finding of this latter study was that eyes identified as 
improved--defined as a disappearance of structural abnormality on color fundus photography--
showed a statistically significant increase in the group mean MS (mean 1.13dB; SE 0.23, 
p<0.001) at 12 months 72. Another study that compared the outcomes in early AMD (AREDS 
grade 2 7) and in intermediate AMD (AREDS grade 3 7) to those in normal individuals found a 
significant worsening in LLVA for each AMD group (p<0.05) 11. The reduction in LLVA was 
associated with a reduction in foveal DLS (r²=0.60, p<0.01) 11. In early to intermediate AMD 
(AREDS grade 2 and 3 7), a reduction of parafoveal MS is associated with a reduction in VA 
and in contrast sensitivity (CS) (r=0.59 and r=0.35 respectively, p<0.01)45. 
In a separate study of individuals with intermediate stage AMD (Beckman classification19), 
neither MS nor foveal DLS were associated with a low luminance deficit (LLD)--defined as the 
difference between VA and LLVA--or with the self-reported outcome to a 10-item night vision 
questionnaire.  Nevertheless, LLD was significantly associated with difficulty under low 
luminance levels 77.
In individuals with nAMD who had previously received anti-VEGF therapy, MS (out to 20˚ 
eccentricity) was moderately correlated with both VA (r=0.54) and CS (r=0.53) separately and, 
to a lesser extent, with reading speed (r=0.37 all p<0.001) 56. In those undergoing anti-VEGF 
treatment, however, no association was present between the MS and either VA or CS 30,43. 
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Other studies have shown that both DLS and VA improve up to either 6 months 48 or 12 months 
43 of anti-VEGF therapy; however, the association between DLS and VA was not determined. 
In subfoveal CNV, an increase in the area of absolute DLS loss is associated with a decline 
in both reading acuity (r=0.52; p=0.01) and reading speed (r=-0.48; p=0.02) 18.
In GA manifesting absolute loss of DLS and a central island of residual vision (foveal sparing), 
the MS out to 20° eccentricity was moderately associated with reading speed (r²=0.5) 5. As an 
improvement in reading is a major goal of vision rehabilitation, microperimetry provides 
additional information about the location and size of the area(s) of residual function, allowing 
for a realistic estimation of reading ability and the likely outcome of rehabilitation 5,23. 
The multifocal electroretinogram (mfERG) provides objective, topographical, 
electrophysiological information about central retinal function. Two studies compared 
microperimetry and mfERG 49,69. In early AMD (Wisconsin Age-related Maculopathy Grading 
system 35), a significant correlation was present between the mfERG response amplitude 
density (N1-P1) and MS (r=0.69, p<0.01) 49; however, there was no association for 
intermediate AMD (Beckman classification19) 69. This latter study found a greater reduction in 
the MS than in the mfERG (p<0.001), suggesting that the two measures assess different 
aspects of retinal dysfunction 69.
In summary, VA, CS and reading ability have historically been used as outcome measures in 
ophthalmic clinical research. Microperimetry has more recently become an additional outcome 
measure. MS exhibits a wide range of values in the presence of relatively good VA in early to 
intermediate AMD3 (International Classification and Grading System 8).  It is able to detect 
progressive improvements in AMD, consistent with color fundus photographs, when no 
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change is observed in VA or LLVA. There is conflicting evidence as to the strength of the 
associations between DLS and VA, CS and reading ability 43,71,72. Reading ability is an 
important factor when considering visual rehabilitation: microperimetry gives additional 
relevant information with respect to the area and location of residual function. 
E. Microperimetry as an outcome measure in clinical trials of medical or 
surgical intervention
Microperimetry has been included as an outcome measure in 17 included articles describing 
clinical trials of medical and/ or surgical interventions for AMD.In individuals undergoing 
treatment with ranibizumab for AMD, MS, measured with the MAIA microperimeter, was at a 
maximum of 17dB for a central retinal thickness of 210μm. MS declined as the thickness 
increased, reaching a minimum of 7dB at a thickness of 320-339μm, and declined as the 
thickness decreased, reaching a minimum of 15dB at a thickness of <160μm 4. These findings, 
however, cannot be compared with other studies as both the microperimetry and the method 
of measuring retinal thickness were not reported. A similar finding was noted with 
bevacizumab therapy: MS increased following a reduction in retinal thickness 29 and 
decreased with increasing retinal thickness (r=-0.54, p<0.01); 55 however, neither of these 
latter studies specified the thickness boundaries used in the retinal thickness measurements. 
It has been suggested that the improvement in MS occurs from the reduction in RPE lesion 
area with treatment rather than from a reduction in the retinal thickness, as a whole 35. 
The relationship between DLS and specific AMD morphology, as identified by SD-OCT, has 
been studied in previously untreated patients with nAMD who subsequently received 
aflibercept 62. The greatest improvement in DLS (measured with the MP-1 microperimeter), 
occurred 3 months after the start of therapy; areas exhibiting a reduction in either a serous 
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PED or subretinal fluid exhibited the greatest improvement in group mean MS of 5.5dB and 
4.0dB respectively (p<0.001). Areas with fibrovascular PED or with an intra-retinal cystoid 
space also improved, but to a lesser extent (group mean improvements 2.3dB and 1.7dB, 
respectively) 62. In an earlier study, DLS improved following ranibizumab therapy in previously 
untreated patients with nAMD. The most marked improvement occurred at stimulus locations 
which were associated with a reduction in subretinal fluid, intraretinal fluid or intraretinal 
cystoid space 60. 
Although all trials of anti-VEGF therapy involving microperimetry report an improvement in 
DLS from baseline, the results of these studies are equivocal with respect to the duration of 
therapy beyond which the DLS ceases to improve. A number of studies have found that DLS 
continues to improve up until 12 months, the time at which the studies ended 
13,25,39,43,60;however, two studies suggest that DLS does not improve beyond that recorded after 
one week of treatment 9,35. DLS can also decline following withdrawal of anti-VEGF therapy. 
Individuals with stable nAMD, who ceased anti-VEGF therapy, exhibited a reduction in DLS 
during the follow-up period (at least 3 visits over 7 months) when compared with those that 
continued to receive treatment 4. It was speculated that the reduction in DLS may have 
resulted either from photoreceptor atrophy over time that was too subtle to be identified by VA 
or that CNV could be occurring at a subclinical level below that required by the United Kingdom 
NICE guidelines for an anti-VEGF injection 4. 
Two trials with unsuccessful outcomes utilized microperimetry as an outcome measure. One 
assessed the outcome of transpalpebral electrotherapy as a treatment for early to intermediate 
AMD (AREDS grade 2, 3 and 47), and the another evaluated the outcome of photodynamic 
therapy combined with intravitreal triamcinolone as a treatment for nAMD 6,17. Neither study 
found a sustained improvement in either DLS, VA, or CS, following treatment. 
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Macular translocation surgery (MT360) involves a peripheral retinectomy of 360˚ at the ora 
serata, following which the subfoveal CNV is removed and the whole retina is rotated such 
that the fovea is located away from the removed CNV. The retina is then reattached. In one 
study, distance VA, near VA, and reading speed improved post-operatively 12. DLS was 
specified in terms of the median retinal sensitivity score (MRSS) obtained with the MP-1 
microperimeter. The 12 month post-operative group mean MRSS was better (2.5dB, SD 4.3) 
in the foveal surgical area compared to the retinal area where the CNV had been removed 
(<0dB) 12; however, the MRSS had not been evaluated prior to surgery; therefore it is not 
possible to evaluate whether the surgery improved visual function. Another study found that 
the MRSS only improved in lesions greater than 4 disc areas 41; however, the two studies 
evaluated the outcome of the translocation surgery by differing methods. The first determined 
the MRSS at areas of healthy retina compared to that at the surgical sites 12, whereas the 
second compared the difference in the MRSS for the pre- and 12-month post-operative areas 
41.
Two RCTs examined the effect of lutein supplementation on macular pigment optical density 
and the subsequent effect on visual function. One RCT found that, although lutein 
supplementation increased the macular pigment density, there was no improvement in MS 
after 6 months of lutein supplementation 68.  Macular pigment density was also weakly 
correlated with DLS (r =0.25, p =0.027) 68. The second RCT examined differing levels of lutein 
supplementation (10mg, 20mg and a combination of lutein with zeaxanthin) with placebo. After 
two years of supplementation, the group mean MS, obtained with the MP-1 microperimeter, 
was greater for the groups receiving 10mg (13.37 dB) or 20 mg of lutein (12.55 dB) compared 
to the control group (10.32 dB, p<0.05) 32. 
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It is clear that microperimetry has the ability to detect changes in visual function arising from 
a variety of interventions for AMD. All studies suggest that MS improves following anti-VEGF 
treatment as retinal thickness decreases and nAMD-associated lesions improve. The extent 
of any such improvement in MS beyond 12 months is unknown.
III. Discussion
The quality of evidence varied among the 52 articles. Overall, none of the RCTs directly 
analysed the utility of microperimetry in the assessment of visual function in AMD but, as would 
be expected, evaluated a specific medical therapy using microperimetry as one of various 
outcome measures. Over half of the studies included in this review were observational in 
design and, therefore, have a consequent risk of selection bias, information bias, or 
confounding bias 26. Many studies had limitations in the quality of reporting of the 
microperimetry outcomes and/or of the SD-OCT methods and analysis (Table 1). Comparison 
between studies was also confounded by the differences in the classification systems for early 
and intermediate AMD. Four studies did not include the classification method 5,23,28,38 . An 
additional difficulty in comparing studies arose from the differences in the dynamic range 
between the various microperimeters used in the studies.
The majority of studies used the summary statistic MS, which is not age-corrected, and many 
of the studies did not report either the number or the spatial location of the stimuli upon which 
the MS was based 4,6,16,22,32,33,39,41,45,52. Only 12 of the studies analysed the DLS at each given 
stimulus location 28,38,53,57,60–63,65,72–74. From the 52 included studies, two of the studies 3,16 
utilised location-specific probability analysis of the measured DLS compared to the 
corresponding age-corrected normal value, as is conventional practice in SAP. Despite the 
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latter probability analysis enabling separation of focal from diffuse defects 31, such an 
approach was not utilised in these two studies. 
The absence of a robust statistical analysis software package for microperimetry that would 
separate focal from diffuse loss and that is comparable to that widely used in SAP currently 
limits the usefulness of the technique. Such analysis would enable a more clinically relevant 
evaluation of the microperimetry outcomes, particularly their association with structure. The 
various microperimeter manufacturers should be encouraged to develop such a package to 
allow this more comprehensive method of assessing abnormal visual function. In late stage 
AMD, this type of analysis would also need to be corrected for the presence for any retinal 
locus 14. 
The clinical value of microperimetry has not yet been assessed against other functional 
biomarkers of AMD, such as flicker sensitivity and dark adaptation, known to be sensitive to 
AMD disease severity 15,47 Microperimetry offers detailed topographical information relative to 
traditional measures of foveal function such as VA and CS. In addition, microperimetry was 
superior to VA in detection of subtle AMD changes in a longitudinal study over one year 72. 
The investigation of microperimetry in comparison with dark adaptation in early AMD would 
be of value and enable clearer clinical recommendations for microperimetry.
Notwithstanding the above limitations, it is clear that there is a strong association between the 
magnitude of the DLS and a number of classic signs associated with AMD. Disruptions of the 
EZ band and RPE are associated with reduced DLS despite the maintenance of good VA 
29,34,38,49,74. OS thinning and RPE thickening are both associated with reduced MS, in early 
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AMD 3. A thickening and a thinning of the whole retina in CNV are each associated with a 
reduced MS 4,29,55.  
IV. Conclusion
The current microperimetric literature is of varying quality, but has been improving in recent 
years. The current lack of consistency in the microperimetric techniques and in the analysis of 
DLS, limits the conclusions regarding the use of microperimetry in AMD. Recommendations 
for good clinical practice are, therefore, currently not possible; however, microperimetry 
provides information beyond that of VA and CS in the functional assessment of AMD. When 
combined with SD-OCT, it gives a multimodal representation of AMD morphology and 
associated visual function. Statistical analysis software similar to that used in SAP would 
render microperimetry a more robust procedure. The development of a multimodal 
topographical classification system for all stages of AMD based upon combined 
microperimetry and SD-OCT outcomes represents an exciting prospect.
V. Methods of literature search
The Medline, Ovid, EMBASE and Web of science databases were each searched using the 
search terms in Table 2. The search extended from 1950 (Medline only) to November 2016. 
The search terms were divided into two groups: population and instrument (Table 2). Each 
selected article was required to match at least one search term from each group. Additional 
articles were identified from the references within the publications identified by the primary 
search. The abstracts of articles found from the database search were independently 
assessed by two of the authors (NC and JA) to identify those that met the inclusion criteria.
22
Eligible articles had to include microperimetry undertaken on at least twenty eyes with AMD 
to provide a minimum level of evidence. All articles were required to contain the DLS outcome 
obtained by microperimetry. Preferred retinal location and fixation studies were excluded. Only 
articles that discussed microperimetry in the context of the outcome from other commercially 
available instrumentation were included. Conference abstracts and case reports were 
excluded. Studies where the whole article was not written in English were also excluded.
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Figure 1. A Flow diagram demonstrating the primary identified articles and those 
included and excluded at each stage of the literature review. Adapted from 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis).
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Figure 2. SD-OCT horizontal line scan of an eye with AMD. Right: The external 
limiting membrane, ellipsoid zone, photoreceptor outer segment and retinal 
pigment epithelium are highlighted by the three black lines which are 
continuous with the respective layers. Left: The separation of the RPE from 
Bruch’s membrane due to drusen.
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Figure 3. Top: Infra-red image and Bottom: SD-OCT 
horizontal line scan of an eye with AMD exhibiting a 
reticular pseudodrusen.
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Figure 4. Colour fundus photograph of an eye with AMD exhibiting 
drusen and an area of GA (circled) with visible choroidal vessels.
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Figure 5. SD-OCT horizontal line scan of an eye with AMD exhibiting 
outer retinal tubulations (highlighted). 
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Reference Author and year Study design AMD identification and 
classification
DLS measures used Quality of evidence
3 Acton et al, 2012 Observational: 
case-controlled
Early AMD: International 
Classification and Grading 
System
MS (68 locations within 10°), 
number of TD defects, MD and PSD 
(derived from previous normative 
data)
High
11 Chandramohan 
et al, 2016
Observational: 
case-controlled
Early and intermediate AMD: 
AREDS classification (grades 2 
and 3)
MS (37 locations within 5°), central 
MS (foveal locus and 12 locations at 
1 °) and percentage reduced 
threshold (under 25dB)
High
18 Ergun et al, 2003 Observational: case 
series
nAMD: identified by FA Size of absolute and relative 
scotoma
High
20 Forte et al, 2013 Observational: case 
series
GA: identified with colour fundus 
photography
MS (49 locations within 3.5°), 
Dense scotoma (0dB) and relatively 
dense scotoma (<5dB)
High
27 Hariri et al, 2016 Observational: 
cross-sectional
Early to late AMD (GA): 
identified and classified by OCT 
(presence of drusen = 
intermediate, GA larger than 0.1 
= GA)
MS (in different zones associated 
with GA)
High
34 Iwama et al, 2010 Observational: case 
series
Soft confluent drusen: 
International Classification and 
Grading System
MS (57 locations over 10°, in central 
2° and at specific locations with 
pathomorphology)
High
43 Munk et al, 2013 Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to treatment, 
identified with FA
MS (ETDRS grid areas), Number of 
absolute scotoma (0dB), severe 
relative scotoma (1-6dB), mild 
relative scotoma (7-12dB) and 
normal (>13dB) were counted.
High
48 Ozdemir et al, 
2012
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA and 
OCT
MS (12 locations within 4˚) and 
number of absolute scotoma (0dB) 
from all 76 stimulus locations within 
20˚
High
49 Parisi et al, 2007 Observational: 
case-controlled
Early AMD: classified by 
Wisconsin Age-related 
Maculopathy Grading System
Central MS (4 locations within 2.5˚) 
and paracentral MS(28 locations in 
annuli between 2.5 and 5˚)
High
53 Querques et al, 
2012
Observational: 
cross-sectional
Early to late AMD (GA): 
presence of soft indistinct 
drusen with RPE changes, 
and/or GA, identified with colour 
fundus photography
MS (49 locations within 4.5°), 
pointwise DLS (at specific locations 
with pathomorphology)
High
56 Sato et al, 2015 Observational: 
cross-sectional
nAMD: identified by OCT and 
FA
MS and Median DLS (29 locations 
within 10°)
High
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57 Sayegh et al, 
2014
Observational: case 
series
GA: identified by fundus 
examination
Pointwise DLS (at specific locations 
with pathomorphology)
High
62 Sulzbacher et al, 
2015
Experimental, 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to treatment, 
identified with FA
MS (33 locations within 6°), 
pointwise DLS (at specific locations 
with pathomorphology)
High
65 Vujosevic et al, 
2011
Observational: 
case-controlled
Early to intermediate AMD: 
AREDS classification (stage 2 to 
3)
MS (61 locations within 5°), K value: 
total number of locations <24dB, 
pointwise DLS
High
68 Weigert et al, 
2013
Experimental, RCT Early to late AMD (GA): AREDS 
classification (stage 2, 3, and 4)
MS (41 locations within 6°) High
70 Wu et al, 2013 Observational: 
case-controlled
Intermediate AMD: Beckman 
classification
MS (37 locations within 6°), 
pointwise DLS
High
74 Wu et al, 2014a Observational: 
cross-sectional
Intermediate AMD: Beckman 
classification
Pointwise DLS (at specific locations 
with pathomorphology) and Z score 
(average of 2 examinations in 
relation to normative data)
High
69 Wu et al, 2014b Observational: 
case-controlled
Intermediate AMD: Beckman 
classification
MS (corresponding to mfERG 
hexagons)
High
71 Wu et al, 2014c Observational: 
cross-sectional
Intermediate AMD: Beckman 
classification
MS (5 locations within central 1˚) High
73 Wu et al, 2015a Observational: 
cross-sectional
Intermediate AMD: Beckman 
classification
MS (associated with groups of AMD 
pathology severity) and pointwise 
DLS (at specific locations with 
pathomorphology)
High
72 Wu et al, 2015b Observational: 
longitudinal case-
controlled
Intermediate AMD: Beckman 
classification
MS (37 locations within 6°) and 
pointwise DLS
High
75 Wu et al, 2015c Observational: 
cross-sectional
Intermediate AMD: Beckman 
classification
MS (25 locations within 4°) High
76 Wu et al, 2016a Observational: 
longitudinal case 
series
Intermediate AMD: Beckman 
classification
MS (37 locations within 6°), MS 
within EDTRS grid sections
High
77 Wu et al, 2016b Observational: 
cross-sectional
Intermediate AMD: Beckman 
classification
MS (37 locations within 6°) and 
central MS (5 locations within 1°)
High
5 Amore et al, 2013 Observational: case 
series
AMD: with absolute scotoma 
and central fixation identified by 
microperimetry
Global MS and central MS. Size (in 
degrees) of central spared area 
(ring scotoma patients).
Medium
‘central vision area’ DLS definition not reported
AMD: not stated method AMD is classified 
9 Bolz et al, 2010 Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to treatment MS (foveal locus and circle of 
locations at 3.5˚)
Medium
OCT: boundaries used to define central retinal 
thickness not reported
AMD: method nAMD is identified not stated
36
12 Chieh et al, 2008 Experimental: 
Quasi-experiment 
nAMD Median DLS within surgery areas 
and number of areas with absolute 
scotoma (<0dB)
Medium
AMD: method nAMD is identified not stated
13 Cho et al, 2013 Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to treatment, 
identified by FA and/or OCT
MS (28 locations within 6˚) Medium
OCT: boundaries used to define central retinal 
thickness not reported
17 Dunavoelgyi et 
al, 2011
Experimental: RCT nAMD: naïve to treatment MS (41 locations within 6˚), number 
of locations and size of absolute 
scotoma (0dB) and relative scotoma 
(<10dB)
Medium
AMD: method nAMD is identified not stated
22 Fujii et al, 2003 Observational: 
cross-sectional
nAMD: identified by FA Percentage presence of dense 
central scotoma (defined as having 
>3 locations of <0dB within 1.5°)
Medium
Microperimetry: stimulus location pattern and stimulus 
details not reported
25 Grenga et al, 
2013
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to treatment MS (45 locations over 10˚), number 
of absolute scotoma locations
Medium
Microperimetry: Absolute scotoma definition not 
reported
AMD: method nAMD is identified not stated
29 Hartmann et al, 
2015
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: presence of ˃250μm 
retinal thickness, subretinal fluid 
or PED.
MS (24 locations within 10˚) Medium
OCT: boundaries used to define retinal thickness not 
reported
32 Huang et al, 2015 Experimental: RCT Early AMD: AREDS 
classification (grade 2)
MS (average DLS at 1, 3 and 5° 
from fixation)
Medium
Microperimetry: stimulus pattern not reported
35 Kiss et al, 2009 Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA MS (25 stimulus locations within 
7.9˚), central 0˚, paracentral 3.5˚ 
and eccentric 7.9˚ MS and absolute 
scotoma size.
Medium
Microperimetry: absolute scotoma definition and 
mode of analysis not reported
38 Landa et al, 2011 Observational: 
cross-sectional
Early to late AMD (GA): drusen 
or atrophic changes, and nAMD: 
CNV, intra/subretinal fluid and 
haemorrhages
MS (28 locations), pointwise DLS Medium
Microperimetry: Stimulus degrees not reported
AMD: method AMD is identified or classified not 
stated
41 Mettu et al, 2011 Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA Median DLS (30 locations) and 
percentage non response (<0dB).
Medium
Microperimetry: stimulus degrees not reported
45 Ooto et al, 2015 Observational: 
cross-sectional
Early to late AMD (GA): AREDS 
classification (2,3, or 4)
MS (29 locations within 20˚ and 
parafovea: central 9 locations)
Medium
Microperimetry: how stimulus pattern not reported
52 Pilotto et al, 2016 Observational: case 
series
GA: identified from fundus 
examination
MS and number of locations with 
relatively dense scotoma (≤5dB)
Medium
Microperimetry: stimulus pattern and degrees not 
reported
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51 Pilotto et al, 2011 Observational: 
cross-sectional
GA: identified from fundus 
examination
MS (customised grid within 8˚ 
including all areas of GA), divided 
into 3 groups based on MS, relative 
and dense scotoma rate
Medium
Microperimetry: relative scotoma definition not 
reported
55 Sabour-Pickett et 
al, 2013
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA MS (fixation, central 5° and all 21 
locations within 16˚)
Medium
OCT: retinal boundaries used were ‘thickness 
between outer most boundaries of scan’ however, 
these are not specified.
59 Steinberg et al, 
2016
Observational: 
case-controlled
Early or intermediate AMD with 
reticular pseudodrusen: 
Beckman classification and IR 
images
MS (56 locations) of areas with RPD 
compared to areas without (scotopic 
and mesopic)
Medium
Microperimetry: stimulus degrees not reported
61 Sulzbacher et al, 
2012
Observational: case 
series
nAMD: identified with colour 
fundus photography, OCT and 
FA
MS (33 locations within 6°), 
pointwise DLS (at specific locations 
with pathomorphology)
Medium
Microperimetry: ‘central retinal sensitivity’ definition 
not reported
60 Sulzbacher et al, 
2013
Experimental, 
Quasi-experiment 
(interrupted time-
series)
nAMD: naïve to treatment, 
identified with colour fundus 
photography, OCT and FA
MS (33 locations within 6°), 
pointwise DLS (at specific locations 
with pathomorphology)
Medium
OCT: pathomorphology used within analysis not 
defined and method of identification not reported
63 Takahashi et al, 
2016
Observational: 
cross-sectional
GA: identified by fundus 
examination
MS (57 locations within 10° and 
over specific areas of retinal 
damage)
Medium
Microperimetry: stimulus pattern not reported
23 Giacomelli et al, 
2013
Observational: 
cross-sectional
Advanced AMD MS (19 locations over 10°) Medium:
AMD: method AMD is identified or classified not 
stated
28 Hartmann et al, 
2011
Observational: 
case-controlled
Early to late AMD (GA): 
presence of drusen on fundus 
examination
Ranked DLS threshold values and 
MS (28 locations within 10°), 
pointwise DLS overlying drusen
Medium:
AMD: method AMD is classified not stated
30 Hautamaki et al, 
2014
Observational: 
cross-sectional
nAMD: naïve to treatment MS and ranking order of DLS (28 
locations within 7.5°)
Medium:
AMD: method AMD is identified not stated
4 Alexander et al, 
2012
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: enrolled from anti-VEGF 
clinic
MS, macular integrity index (MAIA 
software)
Poor
Confusing terminology (stable and unstable used to 
refer to both fixation and AMD status)
Microperimetry: stimulus pattern, number of locations, 
algorithm and stimulus details not reported
OCT: scan details not included and boundaries used 
to define retinal thickness not reported
AMD: how nAMD is identified not stated
6 Anastassiou et al, 
2013
Experimental: RCT Early to late AMD (GA): AREDS 
classification (grades 2,3 and 4)
MS (37 locations within 10°) Poor
Microperimetry: stimulus pattern, algorithm and 
stimulus details not defined
38
OCT: scan details not included and method of 
measuring retinal and choroidal thickness not 
reported
16 Dinc et al, 2008 Observational: 
case-controlled
Intermediate AMD: AREDS 
classification (grade 3)
MS (76 locations within 10˚) and 
mean defect.
Poor
Microperimetry: Mean defect derivation not reported, 
assumed it is from MP-1 software, stimulus pattern 
not reported
OCT: scan details not included and boundaries used 
to define central retinal thickness not reported  
33 Iaculli et al, 2015 Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified by OCT and 
FA
MS (8°) Poor
Microperimetry: stimulus pattern and details not 
defined
OCT: scan details not included and boundaries used 
to define central retinal thickness not reported  
39 Lazzeri et al, 
2015
Experimental: 
Quasi-experiment 
(interrupted time-
series)
nAMD: identified with FA MS (33 locations within 6˚) Poor
Confusing terminology: both ‘mean central retinal 
sensitivity’ and ‘mean retinal sensitivity’ used; and 
‘Central retinal thickness’ and ‘central macular 
thickness’ both used. Difference in terms not reported.
Microperimetry: stimulus pattern and details not 
reported 
OCT: scan details not included and boundaries used 
to define central retinal thickness not reported  
Table 1. Quality of evidence of the 52 included articles. AMD: age-related macular degeneration; AREDS: Age-related Eye Disease Study; DLS: 
differential light sensitivity; ETDRS: Early Treatment Diabetic Retinopathy Study; FA: fluorescein angiography; GA: geographic atrophy; MD: 
Mean Deviation; MS: Mean Sensitivity; nAMD: neovascular AMD; OCT: Optical coherence tomography; PSD: Pattern Standard Deviation; TD: 
Total Deviation.
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Table 2. Terms used in the database search (*=truncation: includes various word endings 
into search).
Population Instrument
Age-related Macul* Microperimet*
AMD
ARMD
Macular degeneration
Dry Macular degeneration
Wet Macular degeneration
Senile Macular degeneration
AND
Fundus controlled perimet*
